MedCity News May 16, 2024
Johnson & Johnson’s Proteologix acquisition adds a pipeline of bispecific antibodies, including an experimental treatment for asthma and atopic dermatitis. It’s the latest M&A deal involving molecules addressing TSLP, a key signaling protein involved in inflammation.
Johnson & Johnson is boosting its immunology and inflammation drug pipeline with the acquisition of Proteologix, a startup whose most advanced program is ready for Phase 1 testing in asthma and atopic dermatitis.
According to deal terms announced Thursday, J&J will pay $850 million in cash. San Carlos, California-based Proteologix could receive more depending on the progress of its drug candidates, but no details about the milestones were disclosed.
Lead Proteologix asset PX128 is a bispecific antibody designed to target IL-13 and TSLP. IL-13...
Today's Sponsors
Today's Sponsor